← Leaderboards
Aaron Robert Goldman
University Of Pennsylvania
$1,293,622
Attributed
$2,587,243
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $669.9K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,587,243 · 1
By mechanism
R01$2,587,243 · 1
Top collaborators
- Ravi K Amaravadi4 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Meenhard Herlyn$50,214,821
- Ravi K Amaravadi$13,477,656
- Xiaowei Xu$9,845,570
- Jeffrey D Winkler$6,111,195
- Ronen Marmorstein$40,497,435
Others in their field
Other Rising Stars on “Clinical Trials”
- Kiran Datta · Leidos Biomedical Research, Inc.$292,634,066
- Angee Greer · Ppd Development Lp$82,531,927
- Jessica Ellis · Technical Resources International, Inc.$46,538,640
- Jessica Holden · Technical Resources International, Inc.$37,843,443
- Suma Babu · Massachusetts General Hospital$36,168,406
- Sabrina Paganoni · Massachusetts General Hospital$36,168,406
Research focus
Clinical TrialsAnti-Pd1 AntibodiesAntigen PresentationAdvanced Malignant NeoplasmAutophagocytosisBiotechnologyBraf GeneCancer Clinical TrialCancer ModelCancer PatientCancer TherapyCd8-Positive T-LymphocytesCell DeathCell-Mediated CytolysisCell MembraneCellsCell SurvivalCeramide GlucosyltransferaseChemotherapyCholesterolClinicClinical DataClinically RelevantCollaborations
Grant awards (4)
Resistance mechanisms to autophagy-modulating therapies$654,428
R01 · FY2025 · CA
Resistance mechanisms to autophagy-modulating therapies$621,660
R01 · FY2024 · CA
Resistance mechanisms to autophagy-modulating therapies$641,245
R01 · FY2023 · CA
Resistance mechanisms to autophagy-modulating therapies$669,910
R01 · FY2022 · CA